Title |
Focused Update on Pharmacologic Management of Hypertensive Emergencies
|
---|---|
Published in |
Current Hypertension Reports, June 2018
|
DOI | 10.1007/s11906-018-0854-2 |
Pubmed ID | |
Authors |
Kristin Watson, Rachael Broscious, Sandeep Devabhakthuni, Zachary R. Noel |
Abstract |
Hypertensive emergency is defined as a systolic blood pressure > 180 mmHg or a diastolic blood pressure > 120 mmHg with evidence of new or progressive end-organ damage. The purpose of this paper is to review advances in the treatment of hypertensive emergencies within the last 5 years. New literature and recommendations for managing hypertensive emergencies in the setting of pregnancy, stroke, and heart failure have been published. Oral nifedipine is now considered an alternative first-line therapy, along with intravenous hydralazine and labetalol for women presenting with pre-eclampsia. Clevidipine is now endorsed by guidelines as a first-line treatment option for blood pressure reduction in acute ischemic stroke and may be considered for use in intracranial hemorrhage. Treatment of hypertensive heart failure remains challenging; clevidipine and enalaprilat can be considered for use in this population although data supporting their use remains limited. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 60% |
Unknown | 2 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Scientists | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 96 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 11 | 11% |
Researcher | 10 | 10% |
Student > Bachelor | 10 | 10% |
Student > Doctoral Student | 9 | 9% |
Student > Master | 9 | 9% |
Other | 16 | 17% |
Unknown | 31 | 32% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 43 | 45% |
Pharmacology, Toxicology and Pharmaceutical Science | 7 | 7% |
Nursing and Health Professions | 5 | 5% |
Biochemistry, Genetics and Molecular Biology | 1 | 1% |
Immunology and Microbiology | 1 | 1% |
Other | 7 | 7% |
Unknown | 32 | 33% |